Efficient Production of Chimeric Antigen Receptor (CAR) T Cells with Transgenes Exceeding 10 kb Using Lentiviral Vectors
Journal of Visualized Experiments · 2026
DOI: 10.3791/69121 ↗At a glance
Video/Audio in Journal of Visualized Experiments, 2026. Written by Philipp C Rommel and 3 co-authors. Institution: Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania; Department of Pathology and Laboratory Medicine, Perelm…. Major MEDLINE topics: Lentivirus, Receptors, Chimeric Antigen, T-Lymphocytes. Cited 1 times so far (Crossref); 19 references. Funded by: NCI NIH HHS.
Abstract (original language)
Engineering multiple receptors into chimeric antigen receptor (CAR) T cells has emerged as a powerful strategy to prevent antigen-negative relapse and reduce on-target/off-tumor toxicities. However, manufacturing multi-receptor CAR T cells remains challenging, as increasing lentiviral transgene sizes significantly reduces viral titers and T cell transduction rates. Current production workflows often rely on cell sorting to enrich transduced T cells from low-yield productions. Yet, cell sorting techniques do not increase the absolute number of CAR T cells and add further complexity to the already elaborate manufacturing process. Consequently, these limitations impede the clinical translation of multi-receptor CAR T cells and restrict the development of next-generation immunotherapies. Here, we present a detailed, step-by-step production workflow optimized for generating CAR T cells with large lentiviral transgenes. Using this workflow, we demonstrate size-dependent increases in transduction efficiency across a range of transgene sizes, with the most pronounced enhancement of up to 14.8-fold observed for a 10.1 kb lentiviral vector. Importantly, the workflow supports robust T cell expansion and eliminates the need for cell sorting. By overcoming current size limitations in lentiviral gene transfer, this workflow enables the efficient generation of multi-receptor CAR T cells, thereby facilitating the development of advanced immunotherapies.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania; prommel@pennmedicin…
- Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania.
- Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania.
- Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania; Parker Institute fo…
Funding
- NCI NIH HHS
Cite
APA
Rommel, P. C., Engel, N. W., Levine, B. L., & June, C. H. (2026). Efficient Production of Chimeric Antigen Receptor (CAR) T Cells with Transgenes Exceeding 10 kb Using Lentiviral Vectors. Journal of Visualized Experiments. https://doi.org/10.3791/69121
Vancouver
Rommel PC, Engel NW, Levine BL, June CH. Efficient Production of Chimeric Antigen Receptor (CAR) T Cells with Transgenes Exceeding 10 kb Using Lentiviral Vectors. Journal of Visualized Experiments. 2026. doi:10.3791/69121
BibTeX
@article{Rommel2026,
author = {Rommel, Philipp C and Engel, Nils W and Levine, Bruce L and June, Carl H},
title = {Efficient Production of Chimeric Antigen Receptor (CAR) T Cells with Transgenes Exceeding 10 kb Using Lentiviral Vectors},
journal = {Journal of Visualized Experiments},
year = {2026},
doi = {10.3791/69121}
}
EUVIMED